Latest News and Press Releases

MannKind to Present at 2024 UBS Healthcare Conference

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

Mannkind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of NTM Lung Disease

MORE ADULTS WITH TYPE 1 DIABETES ACHIEVED A1C GOAL (<7%) AFTER SWITCHING FROM MULTIPLE DAILY INSULIN INJECTIONS OR AUTOMATED PUMPS TO INHALED INSULIN

MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment

韓国とオーストラリアの保健当局からも承認取得、台湾は2024年第4四半期に承認取得予定米国で初の患者無作為化 コネチカット州ダンバリ, Sept. 18, 2024 (GLOBE NEWSWIRE) -- 内分泌疾患および希少肺疾患患者を対象とした革新的な吸入治療薬および機器の開発・商業化に取り組んでいる マンカインド・コーポレーション (MannKind Corporation)...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled...

KENT KRESA TO RETIRE FROM MANNKIND’S BOARD OF DIRECTORS; STEVEN B. BINDER TO BE APPOINTED TO THE BOARD